Responses

PDF
Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy
    • Dan Calugaru, Ophthalmologist Univ of Medicine Cluj-Napoca/Romania
    • Other Contributors:
      • Mihai Calugaru, Professor Univ Ophthalmology

    Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy
    Dan Calugaru, Mihai Calugaru
    Department of Ophthalmology, Univ of Medicine Cluj-Napoca/Romania

    Re: Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy. Jeong and Sagong. Br J Ophthalmol 2016; http: /dx.doi. org/ 10.1136/bjophthalmol-2016-309144.

    Dear Editor
    We would like to address several challenges that have arisen from the study by Jeong and Sagong (1), which can be specifically summarized below.
    1. The study included a relatively small sample size of cases examined with a fairly short follow-up period.
    2. Several relevant data are missing in the study. For example, the anatomic types of macular edema (diffuse/cystic changes within neurosensory retina/subretinal/sub retinal pigment epithelium (RPE) fluid/ mixed type) at baseline and at months 3 and 6; the qualitative status of the 4 outer retinal layers (eg, the external limiting membrane band, the ellipsoid zone, the interdigitation zone, and the retinal pigment epithelial band) at presentation as well as the magnitude of changes (disruption/absence) during the study as potential predictors of visual loss/improvement after aflibercept (Eylea; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA) treatment; the percentages of patients with complete polyp regression and...

    Show More
    Conflict of Interest:
    None declared.